doi: 10.1161/CIRCULATIONAHA.107.698597
(Circulation. 2007;115:2461-2463.)
© 2007 American Heart Association, Inc.
Editorial |
Transvenous Implantable Cardioverter-Defibrillator Leads
The Weakest Link
From the Cardiovascular Division, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Mass.
Correspondence to William H. Maisel, MD, MPH, Cardiovascular Division, Beth Israel Deaconess Medical Center, 185 Pilgrim Rd, Baker 4, Boston, MA 02465. E-mail wmaisel@bidmc.harvard.edu
Key Words: Editorials • death, sudden • defects • defibrillation • tachyarrhythmias
An extract of the first 250 words of the full text is provided, because this article has no abstract. |
Transvenous implantable cardioverter-defibrillator (ICD) lead development was an important advance in arrhythmia management. Their evolution has been critical to the wide acceptance of ICDs for the treatment of ventricular arrhythmias and the prevention of sudden cardiac death. Indeed, it is unlikely that the 20-fold increase in annual ICD implants observed during the past 15 years would have occurred without the advent of these leads.1 Compared with their epicardial predecessors, transvenous ICD leads are easier to implant, are less costly, and result in substantially decreased morbidity and mortality.2
Article p 2474
Modern ICD leads consist primarily of electrodes, conductors, and insulation, with a fixation mechanism and a connector to attach the lead to the myocardium and the ICD generator, respectively. ICD leads must withstand hundreds of millions of repetitive cardiac cycles, survive in the hostile environment of the human body, and allow high-voltage energy delivery for defibrillation at a moment’s notice. In total, the demands placed on ICD leads are unparalleled among implantable medical devices. Successful resuscitation of a potentially lethal ventricular arrhythmia by an ICD system depends on successful arrhythmia detection and timely delivery of therapy. Both the ICD generator and the lead are critical components of this system. Although ICD generator malfunctions have recently garnered much attention, failure of an ICD lead also can result in significant clinical events.1,3,4 Oversensing can cause inhibition of pacing or inappropriate shocks, and failure to capture, premature battery depletion, or failure to defibrillate also can occur.5
Unlike ICD generators, which can be explanted
Related Article:
Circulation 2007 115: 2459.
This article has been cited by other articles:
 |
|
 |
|
  C. J. W. Borleffs, L. van Erven, R. J. van Bommel, E. T. van der Velde, E. E. van der Wall, J. J. Bax, F. R. Rosendaal, and M. J. Schalij Risk of Failure of Transvenous Implantable Cardioverter-Defibrillator Leads Circ Arrhythm Electrophysiol, August 1, 2009; 2(4): 411 - 416. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Grace Implantable defibrillators in hypertrophic cardiomyopathy Heart, May 1, 2009; 95(9): 695 - 696. [Full Text] [PDF]
|
|
|
|
 |
|
 G. Boriani, M. Biffi, A. Marziali, I. Diemberger, and C. Martignani A changing scenario in the clinical use of implantable defibrillators: the need for long-term data on lead performance Europace, January 1, 2009; 11(1): 1 - 3. [Full Text] [PDF]
|
|
|
|
|
|
A. Goette, F. Cantu, L. van Erven, P. Geelen, F. Halimi, J. L. Merino, J. M. Morgan, and on behalf of the Scientific Initiative Committee o Performance and survival of transvenous defibrillation leads: need for a European data registry Europace, January 1, 2009; 11(1): 31 - 34. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. C. Saumarez, M. Pytkowski, M. Sterlinski, J. P. Bourke, J. R. Clague, S. M. Cobbe, D. T. Connelly, M. J. Griffith, P. P. McKeown, K. McLeod, et al. Paced ventricular electrogram fractionation predicts sudden cardiac death in hypertrophic cardiomyopathy Eur. Heart J., July 1, 2008; 29(13): 1653 - 1661. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. H. Maisel and D. B. Kramer Implantable Cardioverter-Defibrillator Lead Performance Circulation, May 27, 2008; 117(21): 2721 - 2723. [Full Text] [PDF]
|
|